Insulin allergy; desensitization with crystalline zinc-insulin and steroid tapering

Diabetes Research and Clinical Practice

Volumn 61, Issue 3, 2003, Pages 161-166

  Yokoyama, Hisayo ^a   Fukumoto, Shinya ^a   Koyama, Hidenori ^a   Emoto, Masanori ^a   Kitagawa, Yoshihiro ^b   Nishizawa, Yoshiki ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NONE

Author keywords

Crystalline zinc insulin; Intradermal test; Monomerization; Prednisolone; Protamine

Indexed keywords

ANTIHISTAMINIC AGENT; GLIBENCLAMIDE; GLIMEPIRIDE; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; MELBIN; METFORMIN; PENFIL; PREDNISOLONE; REAGENT; RECOMBINANT HUMAN INSULIN; RECOMBINANT SOMATOMEDIN C; SOMAZON; STEROID; UNCLASSIFIED DRUG;

ADULT; ALLERGIC REACTION; ANAMNESIS; ANAPHYLAXIS; ARTICLE; AUTONOMIC NEUROPATHY; BLINDNESS; BLOOD CELL COUNT; CASE REPORT; CLINICAL FEATURE; DESENSITIZATION; DIABETIC RETINOPATHY; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG MEGADOSE; DRUG SAFETY; DYSPNEA; ENDOCRINE FUNCTION; FOLLOW UP; HLA TYPING; HUMAN; IMMUNOGENICITY; INSULIN ALLERGY; INSULIN BLOOD LEVEL; INTRACUTANEOUS TEST; LABORATORY TEST; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL NEUROPATHY; PHYSICAL EXAMINATION; SIDE EFFECT; SWEATING; TREATMENT OUTCOME; URTICARIA;

EID: 0042261890     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(03)00114-1     Document Type: Article

References (25)

1. Schernthaner G. Immunogenicity and allergenic potential of animal and human insulins. Diab. Care. 16:(Suppl. 3):1993;155-165.
2. Patterson R., Roberts M., Grammer L.C. Insulin allergy; re-evaluation after two decades. Ann. Allergy. 64:1990;459-462.
3. Kumar D. Lispro analog for treatment of generalised allergy to human insulin. Diab. Care. 20:1997;1357-1359.
4. Airaghi L., Lorini M., Tedeschi A. The insulin analog aspart: a safe alternative in insulin allergy. Diab. Care. 24:2001;2000.
5. Brems D.N., Alter L.A., Beckage M.J., et al. Altering the association properties of insulin by amino acid replacement. Protein Eng. 5:1992;527-533.
6. Setter S.M., Corbett C.F., Campbell R.K., White J.R. Insulin aspart: a new rapid-acting insulin analog. Ann. Pharmacother. 34:2000;1423-1431.
7. Brange J., Owens D.R., Kang S., Volund A. Monomeric insulins and their experimental and clinical implications. Diab. Care. 13:1990;923-954.
8. Ottesen J.L., Nilsson P., Jami J., et al. The potential immunogenecity of human insulin and insulin analogues evaluated in a transgene mouse model. Diabetologia. 37:1994;1178-1185.
9. Pratt E.J., Miles P., Kerr D. Localized insulin allergy treated with continuous subcutaneous insulin. Diab. Med. 18:2001;515-516.
10. Yasuda H., Nagata M., Moriyama H., et al. Human insulin analog insulin aspart does not cause insulin allergy. Diab. Care. 24:2001;2008-2009.
11. Lindholm A., Jensen L.B., Home P.D., Raskin P., Boehm B.O., Rastam J. Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes. Diab. Care. 25:2002;876-882.
12. Schernthaner G., Borkenstein M., Fink M., Mayr W.R., Menzel J., Schober E. Immunogenicity of human insulin (Novo) or pork monocomponent insulin in HLA-DR-typed insulin-dependent diabetic individuals. Diab Care. 6:(Suppl. 1):1983;43-48.
13. Grant W., deShazo R.D., Frentz J. Use of low-dose continuous corticosteroid infusion to facilitate insulin pump use in local insulin hypersensitivity. Diab. Care. 9:1986;318-319.
14. Riddle M.C., Schneider J. Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Diab. Care. 21:1998;1052-1057.
15. Bentley G., Dodson E., Dodson G., Hodgkin D., Mercola D. Structure of insulin in 4-zinc insulin. Nature. 261:1976;166-168.
16. Yip C.M., Brader M.L., DeFelippis M.R., Ward M.D. Atomic force microscopy of crystalline insulins: the influence of sequence variation on crystallization and interfacial structure. Biophys. J. 74:1998;2199-2209.
17. Ratner R.E., Phillips T.M., Steiner M. Persistent cutaneous insulin allergy resulting from high-molecular-weight insulin aggregates. Diabetes. 39:1990;728-733.
18. Takatsuki H., Ishii H., Yamauchi T., et al. A case of insulin allergy; the crystalline human insulin may mask its antigenicity. Diab. Res. Clin. Pract. 12:1991;137-139.
19. Kurtzhals P., Schaffer L., Sorensen A., et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes. 49:2000;999-1005.
20. Kumar D. Immunoreactivity of insulin antibodies in insulin-treated diabetics: significance of the beta-chain carboxy-terminal amino acid (B-30) of insulin. Diabetes. 28:1979;994-1000.
21. Chng H.H., Leong K.P., Loh K.C. Primary systemic allergy to human insulin; recurrence of generalized urticaria after successful desensitization. Allergy. 50:1995;984-987.
22. Patterson R., Lucena G., Metz R., Roberts M. Reaginic antibody against insulin; demonstration of antigenic distinction between native and extracted insulin. J. Immunol. 103:1969;1061-1071.
23. van Neerven R.J., Wikborg T., Lund G., et al. Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation. J. Immunol. 163:1999;2944-2952.
24. Valentini U., Cimino A., Rocca L., Pelizzari R., Rotondi A., Tosoni C. CSII in management of insulin allergy. Diab. Care. 11:1988;97-98.
25. Nagai T., Nagai Y., Tomizawa T., Mori M. Immediate-type human insulin allergy successfully treated by continuous subcutaneous insulin infusion. Intern. Med. 36:1997;575-578.